Summary
Recent evidence suggests that iron accumulates in substantia nigra pars compacta of patients with Parkinson’s disease (PD). This finding is compatible with changes in the respiratory chain activity, increase of malondialdehyde concentration (a measure of lipid peroxidation), decrease of enzyme activity of enzymes involved in detoxication of hydrogen peroxide and oxygen radical species, increased MAO-B-activity in this brain area etc. All these data suggest that oxidative stress may play a certain role in the pathobiochemistry of PD. In addition to the description of the neuroprotective mechanism of the MAO-B-inhibitor L-deprenyl a new aspect focuses the role of the endogenous MAO-B substrates “polyamines” which occur both in neurons and glia. A further aspect of this review deals with the role of calcium as cellular toxin. Although of major importance it is not decided yet whether these biochemical changes are of primary or secondary importance to the pathogenesis of PD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anon B (1981) Polyamines as cellular regulators. Med Biol 59 (5-6) Ben-Shachar D, Riederer P, Youdim MBH (1990) The implications of high affinity binding sites for 39Fe on dopamine-melanin and potentiation of iron induced lipid peroxidation for Parkinson’s disease. Eur J Pharmacol (submitted).
Ben-Shachar D, Youdim MBH (1990) Selectivity of melaninized nigrostriatal dopamine neurons to degeneration in Parkinson’s disease may depend on ironmelanin interaction. J Neural Transm [Suppl] 29:251–258.
Birkmayer W, Knoll J, Riederer P, Hars V, Youdim MBH, Marton J (1985) Improvement of life expectancy due to L-deprenyl addition to Madopar treatment in Parkinson’s disease. A long term study. J Neural Transm 64:113–127.
Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (—)Deprenyl leads to prolongation of L-dopa efficacy in Parkinson’s disease. Mol Probl Pharmacopsychiatry 19:170–176.
Bolkenius FM, Seiler N (1986) Role of polyamines in the development of gabaergic neurons. Int J Dev Neurosci 4:217–224.
Boobis AR, Fawthrop DJ, Davies DS (1989) Mechanism of cell death. TIPS 10:275–280.
Braughler JM (1988) Calcium and lipid peroxidation. In: Halliwell B (ed) Oxygen radicals and tissue injury. FASEB, Bethesda, pp 99–106.
Braughler JM, Duncan LA, Chase RL (1986) The involvement of iron in lipid peroxidation: importance of ferric to ferrous rat in initiation. J Biol Chem 261:10282–10289.
Canellakis ZN, Marsh LIL, Bondy PK (1989) Yale J Biol Med 62:481–491.
Cohen G (1988) Oxygen radicals and Parkinson’s disease. In: Halliwell B (ed) Oxygen radicals and tissue injury. FASEB, Bethesda, pp 130–138.
Cohen G, Heikkila RE, McNamee D (1974) The generation of hydrogen peroxide, Superoxide radical and hydroxyl radical by 6-hydroxy-dopamine dialuric acid and related cytotoxic agents. J Biol Chem 249:2447–2459.
Dexter DT, Carter CJ, Well FR, Javoy-Agid F, Agid Y, Lee SN, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389.
Halliwell B (1989) Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 126:35–47.
Halliwell B, Gutteridge JM (1986) Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 246:501–514.
Hayashi O (ed) (1989) Oxygen free radicals and medicine. Elsevier, Amsterdam Heby O (1981) Role of polyamines in the control of cell proliferation and differentiation. Differentiation 19:1–11.
Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334:345–348.
Iacopino AM, Christakos S (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 87:4078–4082.
Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm 2(4):327–340.
Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H (1990) Normal mitochondrial genome in brain from patients with Parkinson’s disease and complex I defect. J Neurochem 55:1810–1812.
Markey S, Kopin I, Trevor A, Castagnoli N Jr (eds) (1986) MPTP: a neurotoxin producing a Parkinsonian syndrome. Academic Press, London.
Orrenius S, McConkey DJ, Bellomo G, Pierluigi N (1989) Role of Ca2+ in toxic cell killing. TIPS 10:281–285.
Pilas B, Sana T, Kalyanarman B, Swartz HM (1988) The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Rad Biol Med 4:285–293.
Riederer P, Sofic E, Rausch W, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52:515–521.
Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in the brains of Parkinsonian patients treated with 1-deprenyl. J Neurochem 46:1349–1356.
Russel DH (1980) Ornithine decarboxylase as a biological and pharmacological tool. Pharmacology 20:117–126.
Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD (1989) A selective increase in particulate Superoxide dimutase activity in Parkinsonian substantia nigra. J Neurochem 53:692–698.
Seiler N (1985) Acetylpolyamines as substrates of amine oxidases. In: Mondovi B (ed) Structure and function of amine oxidases. CRC Press, Boca Raton, pp 21–37.
Seiler N (1989) Metabolism and physiological roles of polyamines. In: Bacharach U, Keimer Y (eds) Physiology of polyamines. CRC Press, Boca Raton, pp 159–179.
Seiler N, Al-Therib MJ (1974a) Putrescine catabolism in mammalian brain. Biochem J 144:29–35.
Seiler N, Al-Therib MJ (1974b) AcetylCoA: 1,4-diaminobutane N-acetylpolyamines in vertebrate organs and subcellular distribution. Biochim Biophys Acta 354:206–212.
Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J Neurochem (in press).
Tetrud JW, Langston W (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245:519–522.
The Parkinson Study Group Datatop (1989) Selegiline and Parkinson’s disease. N Engl J Med 321:1364–1371.
Youdim MBH (1985) Brain iron metabolism: biochemical and behavioural aspects in relation to dopaminergic neurotransmission In: Lajtha A (ed) Handbook of neurochemistry, vol 10. Plenum, New York, pp 731–756.
Youdim MBH (1990) Developmental neuropharmacological and biochemical aspects of iron-deficiency In: Dobbing J (ed) Brain behaviour and iron deficiency. Springer, Berlin Heidelberg New York.
Youdim MBH, Ben-Shachar D, Pollard HB (1991) The effects of iron chelators and calcium antagonists on iron induced neuronal peroxidation. Br J Pharmacol (in press).
Youdim MBH, Ben-Shachar D, Riederer P (1989) Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta Neurol Scand 126:47–54.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag
About this paper
Cite this paper
Youdim, M.B.H., Ben-Shachar, D., Riederer, P. (1990). The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson’s disease. In: Riederer, P., Youdim, M.B.H. (eds) Amine Oxidases and Their Impact on Neurobiology. Journal of Neural Transmission, vol 32. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9113-2_34
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9113-2_34
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82239-5
Online ISBN: 978-3-7091-9113-2
eBook Packages: Springer Book Archive